(NZ)-N-[2,2-difluoro-1-(2-fluorophenyl)ethylidene]-2-methylpropane-2-sulfinamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (NZ)-N-[2,2-difluoro-1-(2-fluorophenyl)ethylidene]-2-methylpropane-2-sulfinamide
• 化学式: C₁₂H₁₄F₃NOS
• 分子量: 277.31
• InChiKey: PIHYTXPRBMDBKO-YBEGLDIGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  48.6
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY<br/>[FR] DÉRIVÉS DE DIHYDROOXAZINE OU D'OXAZÉPINE AYANT UNE ACTIVITÉ INHIBITRICE DE BACE1
  申请人：SHIONOGI & CO

  公开号：WO2014065434A1

  公开（公告）日：2014-05-01

  The present invention provides a compound which has an effect of inhibiting amyloid beta production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid beta proteins. A compound of the formula (I):wherein X is -C(R3a)(R3b)-, -C(R3a)(R3b)-C(R3c)(R3d)- or -C(R3a)=C(R3c)-, R1 is substituted or unsubstituted alkyl or the like,R2a, R2b, R3a, R3b, R3c and R3d are each independently hydrogen, halogen or the like, R4 is hydrogen or halogen,Ring B is substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种化合物，具有抑制淀粉样蛋白β产生的作用，特别是抑制BACE1的作用，并且可用作治疗或预防由淀粉样蛋白β蛋白的产生、分泌和/或沉积引起的疾病的药剂。式(I)的化合物：其中X为-C(R3a)(R3b)-，-C(R3a)(R3b)-C(R3c)(R3d)-或-C(R3a)=C(R3c)-，R1为取代或未取代的烷基或类似物，R2a、R2b、R3a、R3b、R3c和R3d分别独立地为氢、卤素或类似物，R4为氢或卤素，环B为取代或未取代的碳环或取代或未取代的杂环，或其药学上可接受的盐。
• FLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZINES
  申请人：F. Hoffmann-La Roche AG

  公开号：US20150031690A1

  公开（公告）日：2015-01-29

  The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

  本发明提供了一种具有BACE1抑制活性的化合物（I）的制备方法，包括含有它们的制药组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防例如阿尔茨海默病等疾病方面具有用途。
• DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY
  申请人：SHIONOGI & CO., LTD.

  公开号：US20150266865A1

  公开（公告）日：2015-09-24

  The present invention provides a compound which has an effect of inhibiting amyloid β production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid β proteins. A compound of the formula (I): wherein X is —C(R 3a )(R 3b )—, —C(R 3a )(R 3b )—C(R 3c )(R 3d )— or —C(R 3a )═C(R 3c )—, R 1 is substituted or unsubstituted alkyl or the like, R 2a , R 2b , R 3a , R 3b , R 3c and R 3d are each independently hydrogen, halogen or the like, R 4 is hydrogen or halogen, Ring B is substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种化合物，具有抑制淀粉样蛋白β产生的作用，特别是抑制BACE1的作用，并且可用作治疗或预防由淀粉样蛋白β蛋白的产生、分泌和/或沉积引起的疾病的药物。化合物的公式（I）如下：其中X为—C（R3a）（R3b）—，—C（R3a）（R3b）C（R3c）（R3d）—或—C（R3a）═C（R3c）—，R1为取代或未取代的烷基或类似物，R2a，R2b，R3a，R3b，R3c和R3d分别独立地为氢、卤素或类似物，R4为氢或卤素，环B为取代或未取代的碳环或取代或未取代的杂环，或其药学上可接受的盐。
• 2-Amino-6-(Difluoromethyl)-5,5-Difluoro-6-Phenyl-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors
  申请人：H. Lundbeck A/S

  公开号：US20170319564A1

  公开（公告）日：2017-11-09

  The present invention is directed to compounds of formula (I) which are inhibitors of the BACE 1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.
• 2-AMINO-6-(DIFLUOROMETHYL)-5,5-DIFLUORO-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
  申请人：H. Lundbeck A/S

  公开号：US20190000823A1

  公开（公告）日：2019-01-03

  The present invention is directed to compounds of formula (I) which are inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.